Zometa

Zometa (Zoledronic Acid Monohydrate) is an intravenous bisphosphonate used to manage bone conditions. This medication helps reduce bone pain and prevent complications from bone metastases. It is prescribed under medical supervision for osteoporosis and hypercalcemia of malignancy.

Zometa is commonly used to treat bone metastases, osteoporosis, and hypercalcemia of malignancy. It helps reduce bone pain and lower the risk of fractures in patients with bone metastases. The medication works by slowing bone breakdown and improving bone density.

Zometa may cause flu-like symptoms such as fever, chills, or fatigue shortly after administration. Some patients experience bone or joint pain, nausea, or headache. These effects are usually temporary and may lessen with subsequent doses.

Patients should stay well-hydrated before and after receiving Zometa to reduce the risk of kidney problems. It is important to inform your healthcare provider about any kidney issues or dental procedures planned. Regular monitoring may be required during treatment.

Zometa may interact with other medications affecting kidney function, such as diuretics or NSAIDs. Combining it with aminoglycosides or other bisphosphonates could increase the risk of low calcium levels. Always disclose all medications to your healthcare provider before starting treatment.